Merck & Co., Inc. (MRK) yesterday, won the US Food and Drug Administration’s (FDA) Accelerated Approval for its breakthrough cancer therapy, Keytruda. It beat Bristol-Myers Squibb Co. (BMY) by becoming the first company first to get approval for a PD-1 inhibitor drug in the US. Keytruda has been approved for the treatment of advanced melanoma in patients who have failed treatments with Bristol-Myers’ Yervoy and other drugs.
Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc.’s (NYSE:MRK) respective cancer immunotherapies, Opdivo and Keytruda, showed promising results for the treatment of Hodgkin’s lymphoma in two separate studies, researchers announced Saturday.
Eli Lilly and Co (NYSE:LLY) announced two separate collaborations, one with Merck & Co., Inc. (NSYE:MRK), and the other with Bristol-Myers Squibb Co (NYSE:BMY), to conduct the clinical tests of cancer drugs developed by both companies.
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced a collaboration agreement with the Japanese pharmaceutical company Eisai Co., Ltd (ADR) (OTCMKTS:ESALY). They will carry out multiple clinical trials to analyze the safety and efficacy of Merck’s KEYTRUDA in combination with Eisai’s cancer compounds, including LENVIMA and HALAVEN.
By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) meeting, promises to produce longer-lasting remissions.
The US Food and Drug Administration (FDA) on Monday approved Bristol-Myers Squibb Co’s (NYSE:BMY) top pipeline asset, Opdivo, for the treatment of advanced skin cancer, five months after Japan gave a green signal to the drug for the said indication.
AstraZeneca plc (ADR) (AZN) presented positive data from early-stage studies for its immunotherapy drug MEDI4736 at the ongoing European Society of Medical Oncology (ESMO) 2014 Congress. The studies evaluated the drug as a monotherapy, as well as a combination treatment with experimental drug tremelimumab, for the treatment of Non-small cell lung cancer (NSCLC).